Filing Analysis
Other SEC Filing
Filed May 07, 2026
LOW
Silence Therapeutics plc reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The filing was signed by Iain Ross, who continues to serve as the Interim Principal Executive Officer.
Red Flags
- The company is operating under an Interim Principal Executive Officer (Iain Ross), indicating a lack of permanent top-tier management stability.
Key Facts
- The company announced Q1 2026 financial results on May 7, 2026.
- The report was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Iain Ross is acting as both the Interim Principal Executive Officer and Chairman of the Board.
- The company is incorporated in England and Wales and maintains its principal executive offices in London.
Regulation FD Disclosure
Filed Mar 05, 2026
LOW
Silence Therapeutics plc announced its fourth quarter and full year 2025 financial results on March 5, 2026. The company also released an updated corporate presentation detailing its business updates and pipeline progress.
Red Flags
- The company is currently led by an Interim Principal Executive Officer, indicating a pending permanent leadership transition
Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025
- Updated corporate presentation was issued in March 2026
- Iain Ross is currently serving as Interim Principal Executive Officer and Chairman of the Board
- The filing includes Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure)
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.